Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-naïve HIV-infected patients: results of the ENCORE1 Study

L. Dickinson^*, J. Amin, L. Else, M. Boffito, D. Egan, A. Owen, S. Khoo, D. Back, C. Orrell, A. Clarke, M. Losso, P. Phanuphak, D. Carey, D. A. Cooper, S. Emery, R. Puls

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review